- Home
- AMAL vs INBX Comparison
AMAL vs INBX Comparison
Compare AMAL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | INBX |
|---|---|---|
| Founded | 1923 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.7M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AMAL | INBX |
|---|---|---|
| Price | $41.94 | $133.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $36.00 | ★ $150.00 |
| AVG Volume (30 Days) | 114.6K | ★ 486.3K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | N/A |
| P/E Ratio | $49.96 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $25.13 | $12.80 |
| 52 Week High | $44.01 | $155.29 |
Technical Indicators
Market Signals| Indicator | AMAL | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 66.58 |
| Support Level | $36.50 | $69.30 |
| Resistance Level | $43.33 | $155.29 |
| Average True Range (ATR) | 1.31 | 13.75 |
| MACD | -0.05 | 0.62 |
| Stochastic Oscillator | 77.16 | 69.23 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.